Pfizer Inc. agreed to pay $43bn in cash for antibody-drug conjugate (ADC) developer Seagen Inc. earlier this month. The US pharma giant said Seagen’s four approved products – three ADCs and a small molecule cancer drug – plus candidates in its pipeline should generate $10bn in annual revenue by 2030. This puts Pfizer less than $5bn away from achieving its goal of adding $25bn in new revenue by 2030 through business development activities.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?